Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Matthew H. Daniels is active.

Publication


Featured researches published by Matthew H. Daniels.


Bioorganic & Medicinal Chemistry Letters | 2010

Purine derivatives as potent γ-secretase modulators

Alexey Rivkin; Sean P. Ahearn; Stephanie M. Chichetti; Christopher Hamblett; Yudith Garcia; Michelle Martinez; Jed L. Hubbs; Michael H. Reutershan; Matthew H. Daniels; Phieng Siliphaivanh; Karin M. Otte; Chaomin Li; Andrew Rosenau; Laura Surdi; Joon Jung; Bethany Hughes; Jamie L. Crispino; George Nikov; Richard E. Middleton; Christopher M. Moxham; Alexander A. Szewczak; Sanjiv Shah; Lily Y. Moy; Candia M. Kenific; Flobert Tanga; Jonathan C. Cruz; Paula Andrade; Minilik Angagaw; Nirah H. Shomer; Thomas A. Miller

The development of a novel series of purines as gamma-secretase modulators for potential use in the treatment of Alzheimers disease is disclosed herein. Optimization of a previously disclosed pyrimidine series afforded a series of potent purine-based gamma-secretase modulators with 300- to 2000-fold in vitro selectivity over inhibition of Notch cleavage and that selectively reduces Alphabeta42 in an APP-YAC transgenic mouse model.


Journal of Medicinal Chemistry | 2013

Discovery of 1-[3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron Dual Kinase Inhibitor with Preferential Affinity for the Activated State of c-Met

Alan B. Northrup; Matthew H. Katcher; Michael D. Altman; Melissa Chenard; Matthew H. Daniels; Sujal V. Deshmukh; Danielle Falcone; David J. Guerin; Harold Hatch; Chaomin Li; Wei Lu; Bart Lutterbach; Timothy J. Allison; Sangita B. Patel; John F. Reilly; Michael H. Reutershan; Keith Rickert; Craig Rosenstein; Stephen M. Soisson; Alexander A. Szewczak; Deborah Walker; Kevin J. Wilson; Jonathan R. Young; Bo Sheng Pan; Christopher J. Dinsmore

This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under investigation as a treatment for cancer. The design of 11r was based on the desire to reduce time-dependent inhibition of CYP3A4 (TDI) by members of this structural class. A novel two-step protocol for the synthesis of benzylic sulfonamides was developed to access 11r and analogues. We provide a rationale for the observed selectivity based on X-ray crystallographic evidence and discuss selectivity trends with additional examples. Importantly, 11r provides full inhibition of tumor growth in a c-Met amplified (GTL-16) subcutaneous tumor xenograft model and may have an advantage over inactive form kinase inhibitors due to equal potency against a panel of oncogenic activating mutations of c-Met in contrast to c-Met inhibitors without preferential binding to the active kinase conformation.


Organic Letters | 2011

Palladium-Catalyzed Cross-Coupling of Benzyl Thioacetates and Aryl Halides

Krista M. Wager; Matthew H. Daniels

A method for preparing benzyl aryl thioethers utilizing an in situ deprotection of benzyl thioacetates as an alternative to free thiols as starting materials has been developed and optimized. Good to excellent yields of diverse benzyl aryl thioethers are obtained with air-stable, odor-free, and easy to prepare thioesters. A one-pot protocol for forming benzyl aryl thioethers from a benzyl halide, potassium thioacetate, and an aryl bromide has also been demonstrated.


Archive | 2014

Novel compounds that are erk inhibitors

Kevin J. Wilson; David J. Witter; Matthew H. Daniels; Angie R. Angeles; Phieng Siliphaivanh; David L. Sloman; Brendan M. O'boyle; Danielle Falcone; Catherine White; Ron Ferguson; Wei Zhou; Kathryn Lipford; Umar Faruk Mansoor; Salem Fevrier; Xianhai Huang; Ravi Kurukulasuriya; Judson E. Richard; Shuyi Tang; Christopher W. Boyce; Joseph A. Kozlowski; Raman K. Bakshi; Ganesh Babu Karunakaran


Archive | 2009

Compounds that are erk inhibitors

Kevin J. Wilson; David J. Witter; Phieng Siliphaivanh; Kathryn Lipford; David L. Sloman; Danielle Falcone; Brendan M. O'boyle; Umar Faruk Mansoor; Jongwon Lim; Joey L. Methot; Christopher W. Boyce; Lei Chen; Matthew H. Daniels; Salem Fevrier; Xianhai Huang; Ravi Kurukulasuriya; Ling Tong; Wei Zhou; Joseph A. Kozlowski; Milana Maletic; Bidhan A. Shinkre; Jayanth Thiruvellore Thatai; Raman K. Bakshi; Ganesh Babu Karunakaran


Tetrahedron Letters | 2011

The development of a Selectfluor®-mediated oxidative Mannich reaction

Matthew H. Daniels; Jed L. Hubbs


Archive | 2013

3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF

Kenneth Jay Barr; John Maclean; Hongjun Zhang; Richard Beresis; Neville J. Anthony; Matthew H. Daniels; Blair T. Lapointe; Nunzio Sciammetta


Archive | 2011

NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS

Yongqi Deng; Liang Zhu; Gerald W. Shipps; Sie-Mun Lo; Binyuan Sun; Xiaohua Huang; Corey Beinstock; Alan Cooper; Xiaolei Gao; Xin Yao; Hugh Zhu; Joseph Kelly; Sobhana Babu Boga; Abdul-Basit Alhassan; Jayaram R. Tagat; Umar Faruk Mansoor; Kevin J. Wilson; Brendan M. O'boyle; Matthew H. Daniels; Adam J. Schell; Phieng Siliphaivanh; Christian Fischer


Archive | 2011

PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS

M. Arshad Siddiqui; Yang Nan; Mehul F. Patel; Panduranga Adulla P. Reddy; Umar Faruk Mansoor; Zhaoyang Meng; Lalanthi Dilrukshi Vitharana; Lianyun Zhao; Amit K. Mandal; Duan Liu; Shuyi Tang; Andrew Mcriner; David B. Belanger; Patrick J. Curran; Chaoyang Dai; Angie R. Angeles; Liping Yang; Matthew H. Daniels


Archive | 2015

CARBAMATE BENZOXAZINE PROPIONIC ACIDS AND ACID DERIVATIVES FOR MODULATION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE

Thomas D. Aicher; Chad A. Vanhuis; John Maclean; Brian M. Andresen; Kenneth Jay Barr; Corey Bienstock; Matthew H. Daniels; Kun Liu; Yuan Liu; Catherine White; Nunzio Sciammetta; Vladimir Simov

Researchain Logo
Decentralizing Knowledge